-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Revolution Medicines, Maintains $67 Price Target

Benzinga·04/28/2025 13:23:14
Listen to the news
Wedbush analyst Robert Driscoll reiterates Revolution Medicines (NASDAQ:RVMD) with a Outperform and maintains $67 price target.